Yamamoto Yasuto, Uchiyama Masateru, Iguchi Kazuhito, Kawai Kento, Imazuru Tomohiro, Kawamura Masafumi, Shimokawa Tomoki
Department of Cardiovascular Surgery, Teikyo University, Tokyo, Japan.
Department of Cardiovascular Surgery, Teikyo University, Tokyo, Japan.
Transplant Proc. 2022 Mar;54(2):476-481. doi: 10.1016/j.transproceed.2021.12.009. Epub 2022 Jan 28.
Recent evidence has pointed to the promising benefits of using specific immunosuppressive herbal compounds to prolong transplant allograft survival. In this study, we investigated the effects of glycyrrhizic acid (GA), a major component of licorice, in a model of murine heart transplantation. CBA (H2) mice were transplanted with a fully-MHC mismatched C57BL/6 (H2) heart allograft and subsequently received daily intraperitoneal administration of normal saline or 0.02, 0.2, or 2.0 mg/d of GA for 7 consecutive days. Untreated CBA recipients, with a median survival time (MST) of 7 days, and groups receiving 0.02mg/d (MST, 8 days) or 0.2mg/d (MST, 9 days) of GA acutely rejected C57BL/6 cardiac allografts. But mice treated with 2.0 mg/d of GA demonstrated significant prolongation of allografts (MST, 23 days). Histologic studies showed that cardiac allografts from GA-treated CBA recipients had preserved graft and vessel structure. Moreover, flow cytometric study showed that the percentage of CD4CD25Foxp3 cell (regulatory T cell [Treg]) populations were increased in GA-treated CBA recipients. In a mixed leukocyte culture, splenocytes from GA-treated mice demonstrated suppressed allo-proliferation, in which interleukin (IL)-2 and interferon gamma production were downregulated and IL-10 secretion was upregulated. In conclusion, GA may be a novel promising therapeutic agent to prolong cardiac allograft survival through direct anti-inflammatory effects and induction of Treg populations.
最近的证据表明,使用特定的免疫抑制性草药化合物来延长移植同种异体移植物的存活具有潜在益处。在本研究中,我们在小鼠心脏移植模型中研究了甘草的主要成分甘草酸(GA)的作用。将CBA(H2)小鼠移植完全MHC不匹配的C57BL/6(H2)心脏同种异体移植物,随后连续7天每天腹腔注射生理盐水或0.02、0.2或2.0mg/d的GA。未经治疗的CBA受体,中位生存时间(MST)为7天,接受0.02mg/d(MST,8天)或0.2mg/d(MST,9天)GA的组急性排斥C57BL/6心脏同种异体移植物。但是用2.0mg/d GA治疗的小鼠表现出同种异体移植物的显著延长(MST,23天)。组织学研究表明,来自GA治疗的CBA受体的心脏同种异体移植物保留了移植物和血管结构。此外,流式细胞术研究表明,GA治疗的CBA受体中CD4CD25Foxp3细胞(调节性T细胞[Treg])群体的百分比增加。在混合淋巴细胞培养中,来自GA治疗小鼠的脾细胞表现出同种异体增殖受到抑制,其中白细胞介素(IL)-2和干扰素γ的产生下调,IL-10的分泌上调。总之,GA可能是一种新型的有前途的治疗剂,可通过直接抗炎作用和诱导Treg群体来延长心脏同种异体移植物的存活。